1. In Vivo
  2. >>Deal-Making

Deals In Depth: February 2022

 
• By Maureen Riordan and Deanna Kamienski

Five $1bn+ alliances were penned in February. Topping the list was a potential $2bn deal between Code Biotherapeutics and Takeda to leverage Code Bio’s proprietary targeted 3DNA non-viral genetic medicine delivery platform to design and develop gene therapies for a liver-directed rare disease program, plus central nervous system-directed rare disease programs. Takeda has the right to exercise options for an exclusive license for four resulting programs.

Deals In Depth

In the top February M&A by deal value, Indian biosimilars company Biocon Biologics entered into a definitive agreement to acquire Viatris’ biosimilars business for up to $3.3bn. The biosimilars assets of Viatris (which was formed as a result of the 2019 merger of Pfizer’s Upjohn unit with Mylan) consists of a comprehensive insulins portfolio, including rh-insulin, and biosimilar versions of glargine and aspart; an oncology portfolio including biosimilars for trastuzumab, bevacizumab, and pegfilgrastim; and an autoimmune segment with in-licensed products like Hulio, a biosimilar to AbbVie’s Humira (adalimumab) (from Fujifilm Kyowa Kirin Biologics), and a biosimilar to etanercept (sold by Amgen/Pfizer as Enbrel) under a 2018 agreement with Lupin. Viatris’ global biosimilars business has estimated revenues of $875m for the year 2022. Financing reached $2.8bn in biopharma, $761m in device, and $391m in diagnostics.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.